Articles from Vect-Horus
Martinsried, Germany, and Marseille, France, July 10, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and Vect-Horus, an expert in the design and development of molecular vectors to facilitate targeted delivery of therapeutic molecules and imaging agents, today announced that the companies have entered into a strategic research collaboration to develop RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS).
By Vect-Horus · Via GlobeNewswire · July 10, 2025
PRESS RELEASE
By Vect-Horus · Via GlobeNewswire · April 24, 2025
PRESS RELEASE
By Vect-Horus · Via GlobeNewswire · March 25, 2025

By Vect-Horus · Via GlobeNewswire · January 28, 2025

PRESS RELEASE
By Vect-Horus · Via GlobeNewswire · November 14, 2024

Marseille, France, May 7th - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced its participation at the Viva Technology conference, taking place in Paris, France from May 22-25, 2024.
By Vect-Horus · Via GlobeNewswire · May 7, 2024

Marseille, France, April 22 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the publication of a paper in the open-access scientific journal Pharmaceutics Vol 26 (MDPI).
By Vect-Horus · Via GlobeNewswire · April 22, 2024

Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS). The agreement provides Ionis with a worldwide, exclusive license for a specified number of targets using Vect-Horus’ platform technology ”VECTrans” for systemic delivery of RNA-targeted therapeutics that can cross the blood-brain barrier and address targets in the central nervous system. Ionis has an option to add additional targets to the license. Vect-Horus retains the rights to use its technology, for these specific targets, for all non-RNA-Targeted Medicines.
By Vect-Horus · Via Business Wire · January 30, 2024

VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment Pr. Xavier Declèves to its scientific advisory board (SAB).
By Vect-Horus · Via Business Wire · January 11, 2024

Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo Nordisk A/S. This agreement provides Novo Nordisk with worldwide, exclusive license to use Vect-Horus platform technology ”VECTrans”; for delivery of cargos directed against specified targets . Novo Nordisk has an option to add additional targets to the license.
By Vect-Horus · Via Business Wire · October 30, 2023

VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer. In this role, he will lead the Company’s scientific programs and will be a member of the Management Committee of Vect-Horus.
By Vect-Horus · Via Business Wire · April 3, 2023

Vect-Horus, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Pr. Frédéric Matonti to its scientific advisory board.
By Vect-Horus · Via Business Wire · May 10, 2022

Vect-Horus, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Julia Alterman to its scientific advisory board.
By Vect-Horus · Via Business Wire · March 22, 2022

Vect-Horus and RadioMedix are pleased to announce the FDA clearance of exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the detection and mapping of Low Density Lipoprotein Receptor (LDLR) overexpressed in Glioblastoma Multiforme (GBM). The Phase 1 exploratory study sponsored by RadioMedix will start enrollment upon IRB « Internal Review Board » approval. The study will investigate safety, dosimetry and distribution of 68Ga-RMX-VH in patients with primary or recurrent GBM. The eIND clinical study will proceed in Excel Diagnostic and Nuclear Oncology Center (Houston, TX).
Glioblastoma multiforme is one of the most aggressive brain tumors in humans and is a serious and life-threatening condition. RMX-VH conjugate targets the LDLR, which is overexpressed in many cancer cells, including glioblastoma.
By Vect-Horus · Via Business Wire · July 8, 2021